150 related articles for article (PubMed ID: 35641213)
1. Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort.
Díaz-Casas SE; Briceño-Morales X; Puerto-Horta LJ; Lehmann-Mosquera C; Orozco-Ospino MC; Guzmán-AbiSaab LH; Ángel-Aristizábal J; García-Mora M; Duarte-Torres CA; Mariño-Lozano IF; Briceño-Morales C; Sánchez-Pedraza R
Oncologist; 2022 Mar; 27(2):e142-e150. PubMed ID: 35641213
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
5. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
6. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.
Christopherson K; Lei X; Barcenas C; Buchholz TA; Garg N; Hoffman KE; Kuerer HM; Mittendorf E; Perkins G; Shaitelman SF; Smith GL; Stauder M; Strom EA; Tereffe W; Woodward WA; Smith BD
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):574-581. PubMed ID: 30851348
[TBL] [Abstract][Full Text] [Related]
8. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
Bates M; Sperinde J; Köstler WJ; Ali SM; Leitzel K; Fuchs EM; Paquet A; Lie Y; Sherwood T; Horvat R; Singer CF; Winslow J; Weidler JM; Huang W; Lipton A
Ann Oncol; 2011 Sep; 22(9):2014-2020. PubMed ID: 21289364
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Baez-Vallecillo L; Raghavendra AS; Hess KR; Barcenas CH; Moulder SL; Tripathy D; Valero V; Murthy RK
Breast Cancer Res Treat; 2019 Jul; 176(1):227-234. PubMed ID: 30977027
[TBL] [Abstract][Full Text] [Related]
10. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study.
Wang K; Shi Y; Li ZY; Xiao YL; Li J; Zhang X; Li HY
Eur J Surg Oncol; 2019 Aug; 45(8):1364-1372. PubMed ID: 30837102
[TBL] [Abstract][Full Text] [Related]
11. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
[TBL] [Abstract][Full Text] [Related]
13. Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
Jongen L; Floris G; Boeckx B; Smeets D; Lambrechts D; Vander Borght S; Laenen A; Mann G; Cutler RE; Lalani AS; Neven P; Wildiers H
Breast Cancer Res Treat; 2019 Feb; 174(1):55-63. PubMed ID: 30456437
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study.
Hennigs A; Riedel F; Gondos A; Sinn P; Schirmacher P; Marmé F; Jäger D; Kauczor HU; Stieber A; Lindel K; Debus J; Golatta M; Schütz F; Sohn C; Heil J; Schneeweiss A
BMC Cancer; 2016 Sep; 16(1):734. PubMed ID: 27634735
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.
Harano K; Lei X; Gonzalez-Angulo AM; Murthy RK; Valero V; Mittendorf EA; Ueno NT; Hortobagyi GN; Chavez-MacGregor M
Breast Cancer Res Treat; 2016 Sep; 159(2):367-74. PubMed ID: 27522517
[TBL] [Abstract][Full Text] [Related]
16. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G
J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic factors associated with de novo metastatic breast cancer.
Shen T; Siegal GP; Wei S
Pathol Res Pract; 2016 Dec; 212(12):1167-1173. PubMed ID: 27692496
[TBL] [Abstract][Full Text] [Related]
18. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
19. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Brandão M; Martins-Branco D; De Angelis C; Vuylsteke P; Gelber RD; Van Damme N; van Walle L; Ferreira AR; Lambertini M; Poggio F; Verhoeven D; Barbeaux A; Duhoux FP; Wildiers H; Caballero C; Awada A; Piccart-Gebhart M; Punie K; de Azambuja E
Breast Cancer Res Treat; 2024 Jan; 203(2):351-363. PubMed ID: 37878152
[TBL] [Abstract][Full Text] [Related]
20. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
